Form D · Biotechnology

VISIONGATE INC

Phoenix, AZ · CIK 0001339362

Offering snapshot reported Dec 17, 2019 · SEC filing

Reported sold
$36.6M
Offering amount: $43M
Investors reported
83
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 6, 2013
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$18.3M$36.6MJun 13, 2013: $800,000.00Jun 13, 2013Jun 10, 2014: $4,847,253.00May 26, 2015: $6,206,206.00May 10, 2016: $11,179,852.00Nov 21, 2016: $15,048,042.00Jun 26, 2017: $24,285,945.00Dec 20, 2017: $26,064,119.00Dec 19, 2018: $33,535,586.00Dec 17, 2019: $36,563,440.00Dec 17, 2019

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$33,535,586 → $36,563,440
  • Reported investors73 → 83

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 17, 2019Amendment$36,563,440$3,027,854vs Dec 19, 201883SEC filing
Aug 22, 2019Initial$3,748,247No comparison43SEC filing
Dec 19, 2018Amendment$33,535,586$7,471,467vs Dec 20, 201773SEC filing
Dec 20, 2017Amendment$26,064,119$1,778,174vs Jun 26, 201762SEC filing
Jun 26, 2017Amendment$24,285,945$9,237,903vs Nov 21, 201679SEC filing
Nov 21, 2016Amendment$15,048,042$3,868,190vs May 10, 201642SEC filing
May 10, 2016Amendment$11,179,852$4,973,646vs May 26, 201536SEC filing
Apr 14, 2016Amendment$5,332,200$1,578,700vs Sep 22, 201518SEC filing
Sep 22, 2015Amendment$3,753,500$2,953,500vs Oct 10, 201417SEC filing
May 26, 2015Amendment$6,206,206$1,358,953vs Jun 10, 201425SEC filing
Oct 10, 2014Initial$800,000No comparison2SEC filing
Jun 10, 2014Amendment$4,847,253$4,047,253vs Jun 13, 201314SEC filing
Jun 13, 2013Initial$800,000No comparison1SEC filing
Sep 21, 2012Amendment$4,363,073$214,000vs Jul 24, 201261SEC filing
Jul 24, 2012Amendment$4,149,073$2,188,795vs Oct 11, 201156SEC filing
Oct 11, 2011Amendment$1,960,278$1,835,278vs Oct 12, 201029SEC filing
Oct 12, 2010Initial$125,000No comparison2SEC filing
Sep 1, 2009Amendment$1,780,000No comparison17SEC filing
Apr 10, 2009Initial$490,000No comparisonNot reportedSEC filing
Sep 2, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Sep 10, 2007PaperNot reportedNo comparisonNot reportedSEC filing
Mar 29, 2007PaperNot reportedNo comparisonNot reportedSEC filing
Mar 12, 2007PaperNot reportedNo comparisonNot reportedSEC filing
Sep 19, 2005PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-197905

Source: Form D, filed Dec 17, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Robert C. Bateman Executive
Randy L. Buness Executive
James S. Burns Director
Michael Doherty Director
Sharon K. Everson Director
Maria Forero Director
John Glasspool Director, Executive
Joe Healey Director
Robert A. Heft Director
Thomas C. Miller Director
Alan C. Nelson Director, Executive
Gene F. Pawlick Director
Walter Robb Director
Scarlett Spring Executive
Tanisha June Nichole Villanueva Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
10220 S. 51 St Street Suite 2
Phoenix, AZ, 85044